Korea Investment Partners Puts $2 Million Into US Biotech HexemBio

Korea Investment Partners has invested USD 2 million in HexemBio, a U.S. preclinical biotech developing therapies designed to rejuvenate aging blood stem cells, bringing the company's disclosed total funding to USD 15.5 million.

The investment, made through the KIPUS Trinitas Fund, closed by September 2026, five months after HexemBio announced a USD 10.4 million seed round led by Draper Associates in April. The sequencing matters. KIP evaluated a company that had moved further along its development path than the one earlier investors backed in the spring.

CEO and co-founder Gabriel Levesque Tremblay, PhD, told KoreaTechDesk that the difference was visible in what investors were being asked to underwrite.

"In April, investors were mostly underwriting the science and the regulatory groundwork. By the time Korea Investment Partners came in, studies in our core technology were further along, which made the path to the clinic easier to see. Draper Associates reinvesting across its network mattered to new investors too, since they had been watching our progress up close."

The raise landed in a difficult biotech funding environment. Silicon Valley Bank's H2 2026 Healthcare Industry Trends report counted 618 U.S. healthcare financings in the first half of 2026, the lowest first-half deal count in several years. Biopharma still attracted USD 12.6 billion, but investors concentrated larger amounts among fewer companies. For a preclinical biotech, each subsequent raise becomes a test of how much of the development path has become clearer since the previous check.

Draper's continued participation signaled execution. When HexemBio announced its USD 15.5 million total funding in September, the company identified Draper among existing investors providing additional capital alongside new backers. New investors evaluate accumulated progress while also watching how incumbents respond to what they have observed.

Why a Korean Investor

KIP's stake forms part of a broader U.S. expansion. According to EDaily Market In, KIP's U.S. subsidiary established the USD 100 million KIPUS Trinitas Fund to pursue early-stage investments and larger strategic deals across artificial intelligence, AI infrastructure, aerospace, defense and advanced biotechnology. KIP's portfolio includes biotechnology and healthcare companies in Korea and overseas, and the firm has reportedly been investing in U.S. biotechnology and life sciences for more than a decade.

The firm's U.S. operation is building a local investment network while strengthening collaboration with its Korean headquarters, connecting U.S.-sourced companies with relationships accumulated in Korea and the wider Asian market.

For HexemBio, that connectivity arrived as the company's needs began extending beyond financing. Tremblay described KIP's role in those terms:

"As HexemBio transitions from preclinical development toward the clinic, KIP brings both institutional biotech experience and direct connectivity to the Korean and broader Asian ecosystem."

Asked what an ideal Korean relationship could contribute at this stage, Tremblay identified specific areas: "We're interested in co-development, application development, cosmeceutical and pharma partnership, and CVC engagement."

He added: "Today, the most immediate opportunities are strategic partnerships with Korean pharmaceutical, biotechnology, manufacturing, and cosmetic companies, scientific collaborations, and relationships with leading Asian investors as we expand our global capital base."

Clinical development, commercialization and broader Asian market access sit further down the expansion path.

Korea's Export Base

The partnership targets align with industries where Korea already has international reach. According to the Korea Health Industry Development Institute's first-half 2026 export data, Korean biohealth exports reached USD 16.12 billion, up 17.5% year on year. Pharmaceutical exports hit USD 6.06 billion, including USD 3.97 billion in biopharmaceuticals. Cosmetics exports rose 26.9% to USD 6.98 billion. KHIDI's 2026 outlook projected USD 11.65 billion in pharmaceutical exports for the year and identified expanding contract development and manufacturing capacity as a factor supporting biopharmaceutical export growth.

Those figures give HexemBio's interest in pharmaceutical, cosmeceutical and manufacturing partnerships a sizable base of potential counterparties with international market experience — well before Korea becomes a destination for the company's products.

The deal inverts the usual direction of Korean cross-border venture support: a U.S. biotech with American backing is looking to a Korean investor for connections inside Korea and Asia, rather than a Korean fund helping portfolio companies reach networks overseas. Whether the USD 2 million becomes the starting point for a broader institutional relationship will depend on whether KIP's introductions turn into co-development programs, scientific collaborations or corporate investment — a test that begins now that the money has changed hands.